Read the Official PANTHERx Press Release.

PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole). The drug, an oral film formulation of riluzole, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS).

“PANTHERx is excited to be supporting ALS patients who have been prescribed EXSERVAN through medication dispensing and patient education as part of our proprietary RxARECARE^® model,” said Rob Snyder, President of PANTHERx.

PANTHERx utilizes technology and human capital to create RxARECARE programs tailored to the unique needs of the medications we dispense and the preferences of each patient we support.

About PANTHERx Rare

PANTHERx, part of Envolve Pharmacy Solutions, is one of the largest and fastest growing rare pharmacies in the United States. PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.

PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.

About EXSERVAN (riluzole) oral film

EXSERVAN, an oral film formulation of riluzole, was approved by the U.S. Food and Drug Administration (FDA) in November 2019. EXSERVAN was developed by Aquestive Therapeutics using its PharmFilm^® innovative drug delivery technology. The oral film is placed on top of the patient’s tongue and dissolves. Under the terms of a licensing and supply deal agreement, MTPA is commercializing EXSERVAN in the U.S. and Aquestive is serving as the exclusive sole manufacturer and supplier for the product. For more information, visit www.EXSERVAN.com.

INDICATION

EXSERVAN™ (riluzole) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

IMPORTANT SAFETY INFORMATION

Do not use if you are allergic to riluzole or to any of its ingredients.

Before using EXSERVAN, tell your doctor about all the medicines you take and all your health conditions, including if you:

• Have liver problems.
• Are taking certain drugs known as strong or moderate CYP1A2 inhibitors such as ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, or zileuton.
• Are pregnant or intend to become pregnant during EXSERVAN therapy, or if you are breastfeeding or intend to breastfeed during EXSERVAN therapy.

EXSERVAN can cause serious side effects, including:

Liver Problems: Cases of liver injury, some fatal, have occurred in patients taking riluzole. Consult your doctor promptly if you experience unexplained nausea, vomiting, stomach (abdominal) pain, fatigue, weight loss (anorexia), jaundice (yellowing of the skin or whites of the eyes), and/or dark urine.

Low White Blood Cell Counts (Neutropenia): Tell your doctor if you develop a fever while taking EXSERVAN.

Serious Lung Problems (Interstitial Lung Disease): Tell your doctor if you have problems with your lungs or breathing such as dry cough and difficult or labored breathing. Discontinue EXSERVAN immediately if you develop interstitial lung disease.

The most common side effects include numbness in the mouth or tongue, muscle weakness, nausea, lung problems, high blood pressure, and stomach (abdominal) pain.

These are not all the possible side effects of EXSERVAN. Consult your doctor for medical advice about side effects.

To report side effects, contact Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Use EXSERVAN as prescribed. The recommended dosage for EXSERVAN is 50 mg taken orally twice daily at least 1 hour before or 2 hours after a meal. Place EXSERVAN oral film strip on the top of the tongue where it will adhere and dissolve. Swallow in a normal manner. Do not cut or split the film or take liquids with EXSERVAN. Do not chew, spit, or talk while EXSERVAN is dissolving. Read the Instructions for Use for EXSERVAN.

Please click here to see the full Prescribing Information for EXSERVAN.

Read the Official PANTHERx Press Release.

PANTHERx^® Rare Pharmacy announced today that it was selected by Rhythm Pharmaceuticals as the exclusive U.S. pharmacy distribution partner for IMCIVREE^™ (setmelanotide). The drug was approved by the U.S. Food and Drug Administration (FDA) in November 2020 for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing.

Obesity due to POMC, PCSK1 or LEPR deficiency are ultra-rare diseases caused by variants in POMC, PCSK1 or LEPR genes that impair the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating hunger, energy expenditure and consequently body weight. People living with obesity due to POMC, PCSK1 or LEPR deficiency struggle with extreme, insatiable hunger beginning at a young age, resulting in early-onset, severe obesity. As an MC4R agonist, IMCIVREE is designed to restore impaired MC4R pathway activity arising due to genetic deficits.

“As the exclusive U.S. distribution partner for IMCIVREE, PANTHERx is pleased to provide innovative, life-changing medicines and award-winning white-glove services to people living with obesity due to POMC, PCSK1 or LEPR deficiency,” said Rob Snyder, President of PANTHERx. “PANTHERx’s partnership with Rhythm advances our mutual dedication to improving the lives of members.”

PANTHERx supports tens of thousands of patients across the country, addressing the unique needs of every patient and assisting with their personal journey. Our proprietary RxARECARE^® programs and SWFT^® technology systems have allowed PANTHERx to create fully customizable programs for the 25+ rare and orphan medications dispensed. Communications and support services are tailored to the desires of each patient and the requirements of their life-changing medications. PANTHERx, with its evolving suit of personalized services and culture of sincere care, continues to define rare pharmacy.

For more information about the symptoms, diagnosis, and treatment of obesity due to POMC, PCSK1, or LEPR deficiency please click here.

About PANTHERx^® Rare Pharmacy

PANTHERx Rare Pharmacy, part of Envolve Pharmacy Solutions, is one of the largest and fastest growing rare pharmacies in the United States. PANTHERx Rare transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.

PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.

IMCIVREE Indication and Usage

IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing.

IMCIVREE is not indicated for the treatment of patients with obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign, or for other types of obesity associated with other genetic syndromes and general (polygenic) obesity.

Important Safety Information

WARNINGS AND PRECAUTIONS

• Spontaneous penile erections in males, sexual adverse reactions in females, and depression and suicidal ideation have occurred with IMCIVREE.
• IMCIVREE may cause generalized increased skin pigmentation and darkening of

pre-existing nevi.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in neonates and low birth weight infants: IMCIVREE is not approved for use in neonates or infants.

Most common adverse reactions (incidence ≥23%) were injection site reactions, skin hyperpigmentation, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and spontaneous penile erection.

Please see full Prescribing Information available at www.IMCIVREE.com/hcp for additional Important Safety Information

Read the Official PANTHERx Press Release.

PANTHERx® Rare Pharmacy announces that it has been selected by Alnylam Pharmaceuticals, the leading RNAi therapeutics company, as a very limited distribution pharmacy partner for new drug OXLUMO™ (lumasiran). The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Primary hyperoxaluria (PH) is a group of autosomal-recessive diseases resulting from defects in different enzymes involved in glyoxylate metabolism leading to overproduction of oxalate in the liver. There are 3 types of PH: PH1, PH2, and PH3. PH1 is the most common and most severe type of PH caused by a mutation in the AGXT gene that renders the liver enzyme alanine glyoxylate aminotransferase (AGT) dysfunctional.

OXLUMO is a subcutaneously administered RNAi therapeutic that targets the messenger RNA of the hydroxyacid oxidase 1 (HAO1) gene, which encodes glycolate oxidase (GO) – the liver enzyme responsible for oxalate production and upstream of the AGT enzyme deficient in patients with PH1. By reducing the synthesis of GO, OXLUMO decreases the production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1.
In the pivotal trial, ILLUMINATE-A, OXLUMO was compared against placebo in patients 6 years of age and older with PH1 and an eGFR ≥30 mL/min/1.73 m2. OXLUMO met the primary efficacy endpoint of percent reduction from baseline in 24-hour urinary oxalate excretion corrected for BSA, averaged over Months 3 through 6. Specifically, OXLUMO treatment (N=26) resulted in a mean reduction of 53.5 percent relative to placebo (N=13) (p=1.7 x 10-14), and showed a 65.4 percent mean reduction in urinary oxalate relative to baseline. The most common (≥20%) adverse reaction reported was injection site reaction. Injection site reactions occurred throughout the study period and included erythema, pain, pruritus, and swelling.

“We are honored to partner with Alnylam and provide PANTHERx’s award-winning RxARECARE® services to people living with primary hyperoxaluria type 1,” said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx Rare. “This rare disease medication provides a new option for patients and their families who previously had no approved pharmacologic treatment. PANTHERx is proud to serve as the link between biopharma and patients, delivering medications to the people who need them most.”

For more information about the symptoms, diagnosis, and treatment of primary hyperoxaluria type 1 (PH1), please click here.

About PANTHERx® Rare Pharmacy
PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.
PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.
For more information, visit www.pantherxrare.com

About OXLUMOTM (lumasiran)
OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1. OXLUMO works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. Injection site reactions (ISRs) were the most common drug-related adverse reaction. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate technology designed to increase potency and durability. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly thereafter at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, visit OXLUMO.com.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

For additional information about OXLUMO, please see the full Prescribing Information.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

Read the Official PANTHERx Press Release.

Ernst & Young LLP (EY US) yesterday announced that Dr. Gordon J. Vanscoy, Chairman & CEO of both PANTHERx Rare and RareMed Solutions, was named an Entrepreneur Of The Year^® 2020 National Award winner following selection as an East Central regional award winner in October. This is the first time since 2002 that Pittsburgh has been home to an EY Entrepreneur of the Year National Award winner.

The Entrepreneur Of The Year Awards program is one of the world’s most prestigious competitive forums for entrepreneurs and leaders of high-growth companies. Dr. Gordon Vanscoy was one of 10 national winners announced Thursday, November 19, during a virtual awards celebration. The awards were the culmination of the Strategic Growth Forum^®, one of the nation’s most prestigious gatherings of high-growth, market-leading companies. Dr. Vanscoy was selected by an independent panel of judges from a pool of more than 200 regional award winners.

“I am humbled to have been honored as an EY Entrepreneur of the Year National Award Winner,” said Dr. Gordon J. Vanscoy, Chairman & CEO of PANTHERx Rare & RareMed Solutions. “I accept this award on the shoulders of two fantastic teams. I am so proud of the companies that we have created, but most of all, I am proud of the quality manner in which we serve the rare disease community. To be recognized so auspiciously on the national level in the midst of a pandemic is sobering, but I plan to represent my companies and my hometown of Pittsburgh in an honorable manner.”

Since 1986, EY US has honored entrepreneurs whose ingenuity, spirit of innovation and tenacity have driven their companies’ success, transformed their industries and made a positive impact on their communities. Dr. Gordon Vanscoy will go on to become a lifetime member of the esteemed multi-industry community of award winners, with exclusive, ongoing access to the experience, insight and wisdom of fellow alumni and other ecosystem members in over 60 countries — all supported by EY’s vast resources.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards are nationally sponsored by SAP America and the Kauffman Foundation.

About Entrepreneur Of The Year^®

Entrepreneur Of The Year^® is the world’s most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. Winners go on to compete for the EY World Entrepreneur Of The Year™ title. ey.com/us/eoy

About EY Private

As Advisors to the ambitious™, EY Private professionals possess the experience and passion to support private businesses and their owners in unlocking the full potential of their ambitions. EY Private teams offer distinct insights born from the long EY history of working with business owners and entrepreneurs. These teams support the full spectrum of private enterprises including private capital managers and investors and the portfolio businesses they fund, business owners, family businesses, family offices and entrepreneurs. Visit ey.com/private

About EY

EY exists to build a better working world, helping create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Read the Official PANTHERx Press Release.

PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetinib), which was granted -accelerated approval for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. Developed by Blueprint Medicines, GAVRETO is a once-daily oral precision therapy designed to selectively and potently target oncogenic RET alterations.

RET activating fusions and mutations are key disease drivers in many cancer types, including NSCLC. RET fusions are implicated in approximately 1 to 2 percent of patients with NSCLC.

“PANTHERx is honored to be chosen by Blueprint Medicines to deliver this breakthrough oncology therapy to people living with RET fusion-positive metastatic NSCLC,” said Dr. Gordon Vanscoy, Chairman and CEO of PANTHERx. “As a partner, we are proud to do our part in advancing rare oncology by providing award-winning white-glove services to this previously underserved patient population as part of our innovative RxARECARE™ model.”

About PANTHERx® Rare Pharmacy
PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community.

PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, and ACHC.

Trademarks

Blueprint Medicines, GAVRETO, and associated logos are trademarks of Blueprint Medicines Corporation.

Read the Official PANTHERx Press Release.

PANTHERx^® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical as a limited distribution partner for new drug DOJOLVI^TM (triheptanoin). DOJOLVI™ (a highly purified, pharmaceutical-grade, synthetic seven carbon fatty acid triglyceride) is a specially designed synthetic triglyceride compound, which was developed to treat patients with long-chain fatty acid oxidation disorders (LC-FAOD). DOJOLVI™ provides these patients with a medium-length, odd-chain fatty acid that LC-FAOD patients can metabolize and serve as an alternative source of energy (by increasing intermediate substrates in the Krebs cycle, a key energy-generating process).

“PANTHERx Rare is proud to be chosen by Ultragenyx Pharmaceutical to deliver hope, white glove services, and DOJOLVI™ to people living with LC-FAOD,” said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx. “Our unique RxARECARE™ Team structure ensures that new patients, and all of our patients, receive the level of superior quality, award-wining care that has become synonymous with PANTHERx. We look forward to making a difference in the lives of people living with LC-FAOD.”

LC-FAODs are a group of autosomal recessive genetic disorders characterized by metabolic deficiencies in which the body is unable to convert long-chain fatty acids into energy. The inability to produce energy from fat can lead to severe depletion of glucose in the body, and serious liver, muscle, and heart disease, which can lead to hospitalizations or early death. Currently, LC-FAOD patients are treated with the avoidance of fasting, low-fat/high carbohydrate diets, carnitine, and medium-chain triglyceride (MCT) oil, a medical food product. Despite current therapy, many patients have significant metabolic events including hospitalizations and mortality due to LC-FAOD.

Learn more about the symptoms, diagnosis, and treatment of Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD).

About PANTHERx^® Rare Pharmacy

PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community. PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, ACHC, and CPPA.

Read the Official PANTHERx Press Release.

PANTHERx^® Rare Pharmacy announces that it has been selected by Viela Bio, Inc. as their sole rare pharmacy partner for new drug Uplizna™ (inebilizumab-cdon). The drug has been approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

NMOSD is a rare neuroinflammatory autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure. Each NMOSD attack can lead to further damage and disability.

Uplizna is a humanized monoclonal antibody targeting CD19+ B cells. Inebilizumab-cdon specifically binds to CD19, a cell surface antigen present on pre-B and mature B cell lymphocytes. B cells are believed to play a central role in the pathogenesis of NMOSD.

“PANTHERx is proud to be an exclusive partner with Viela Bio to bring Uplizna to patients suffering from neuromyelitis optica spectrum disorder,” said Dr. Gordon Vanscoy, Chairman and CEO of PANTHERx. “As the sole pharmacy for Uplizna, PANTHERx recognizes the importance of flawless execution as we deliver this breakthrough medication, customized support services, and hope to this vulnerable patient population. We are honored to make a difference in the lives of people living with NMOSD.”

For more information about the symptoms, diagnosis, and treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD), please click here.

About PANTHERx^® Rare Pharmacy

PANTHERx Rare Pharmacy, the largest independent and fastest growing specialty pharmacy in the United States, transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Although the incidence is as common as diabetes, less than 7% of the 7,000 known rare and devastating disorders have an approved therapy. Changes in federal policy and advances in science have led to a surge in FDA orphan drug approvals, providing tremendous hope to the rare disease community. PANTHERx was recently awarded Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy (NASP) and earned the inaugural Accredited Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). PANTHERx is a three-time winner of the prestigious MMIT Patient Choice Award, including the 2020 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania, licensed in all 50 states, and holds accreditations from URAC, NABP, ACHC, and CPPA.

Read the Official PANTHERx Press Release.

PANTHERx Rare Pharmacy (PANTHERx), was officially recognized as a prestigious US Best Managed Company for overall business performance and sustained growth. The US Best Managed Company designation, sponsored by Deloitte Private and The Wall Street Journal, is the preeminent distinction for privately owned and managed businesses in the United States, based on criteria such as management abilities in the areas of strategy, execution, culture, financials, and overall business practices.

As one of only 27 US Best Managed Company honorees, PANTHERx has proven its dedication to not only fostering a culture of growth and sustainability for its associates, but also to providing the best rare pharmacy care and service to its patients afflicted by rare diseases.

“We are incredibly proud of our team’s recognition and what it means for PANTHERx. It’s a sign of our relentless commitment to doing better and being better. As 1PANTHER, we’ll continue to look for novel ways to improve the employee, patient, and partner experience,” says PANTHERx Chairman & CEO, Dr. Gordon Vanscoy. “Our growth has been fueled by innovation, technology, and exceeding expectations for all our patients and partners. PANTHERx is truly unique in the healthcare marketplace. Becoming one of the elite US Best Managed Companies was fueled by incredibly dedicated associates led by an executive team second to none.”

About the Best Managed Companies Program

The Best Managed Companies program is a mark of excellence for private companies. U.S. designees have annual revenues of at least $250 million. Hundreds of private companies around the world have competed for this designation in a rigorous and independent process that evaluates four key criteria in their management skills and practices—strategy, execution, culture and financials. U.S. program sponsors are Deloitte Private and The Wall Street Journal.